Olumiant ® (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Olumiant® (baricitinib): Safety in Patients with Comorbid Demyelinating Disorders

Analysis of the safety of BARI in patients with moderate to severe RA and comorbid demyelinating disorders have not been conducted.

UK_cFAQ_BAR062A_COMORBID_DEMYELINATING_DISORDERS_RA
UK_cFAQ_BAR062A_COMORBID_DEMYELINATING_DISORDERS_RA
en-GB

Exclusion Criteria Related to Demyelinating Disorders in the Baricitinib Clinical Trials

Demyelinating disorders, as defined by the Standardized MedDRA Demyelination Query (SMQ) 20000154 narrow preferred terms, were not specific exclusion criteria in the 4 phase 3 BARI clinical trials, RA-BEAM, RA-BEACON, RA-BUILD, and RA-BEGIN. However, patients were excluded if they had a history or presence of a serious or unstable illness that, in the opinion of the investigator, could

  • constitute a risk when taking an investigational product, or
  • interfere with the interpretation of data.1

See Standardized MedDRA Demyelination Query (SMQ) 20000154 Narrow Preferred Terms for a listing of the narrow preferred terms used to define demyelinating disorders.

Standardized MedDRA Demyelination Query (SMQ) 20000154 Narrow Preferred Terms1

Acute disseminated encephalomyelitis

Marchiafava-Bignami disease

Acute haemorrhagic leukoencephalitis

Multiple sclerosis

Anti-myelin –associated glycoprotein associated polyneuropathy

Multiple sclerosis relapse

Autoimmune demyelinating disease

Multiple sclerosis relapse prophylaxis

Chronic inflammatory demyelinating polyradiculoneuropathy

Myelitis transverse

Clinically isolated syndrome

Myoclonic epilepsy and ragged-red fibres

Concentric sclerosis

Neuromyelitis optica spectrum disorder

Demyelinating polyneuropathy

Neuropathy, ataxia, retinitis pigmentosa syndrome

Demyelination

Noninfectious myelitis

Encephalitis periaxialis diffusa

Noninfective encephalomyelitis

Encephalomyelitis

Optic neuritis

Expanded disability status scale score decreased

Osmotic demyelination syndrome

Expanded disability status scale score increased

Primary progressive multiple sclerosis

Guillain-Barre syndrome

Progressive multifocal leukoencephalopathy

Hypergammaglobulinaemia benign monoclonal

Progressive multiple sclerosis

Leukoencephalomyelitis

Progressive relapsing multiple sclerosis

Leukoencephalopathy

Relapsing-remitting multiple sclerosis

Lewis-Summer syndrome

Secondary progressive multiple sclerosis

MELAS syndrome

Toxic leukoencephalopathy

Marburg’s variant multiple sclerosis

Tumefactive multiple sclerosis

Patients with Comorbid Demyelinating Disorders

None of the patients treated with BARI had a pre-existing condition or historical diagnosis of demyelinating disorders in the 4 phase 3 BARI clinical trials.1

Clinical Recommendations For Patients with Demyelinating Disorders

Lilly cannot provide a recommendation on whether to use BARI in a patient with demyelinating disorders. The treating physician may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors, in formulating an assessment and approach. The treating physician should consider potential risks and benefits of treatment options, and monitor appropriately.

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

BARI = baricitinib

MedDRA = Medical Dictionary for Regulatory Activities

RA = rheumatoid arthritis

Date of Last Review: 31 August 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request